APO Research, Inc.
Talk to an analyst

APO RESEARCH · REPORT

NK1/NK3 Receptor Antagonists

Compare research editions
View pricing & licenses

Selected research

Industry Growth & Trends

Global NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032

Report ID 174017370123 December 2025112 pages

Choose your research edition.

Industry ResearchNK1/NK3 Receptor Antagonists Industry Research Report 2026130 pages · $2,950 USDIndustry Growth & TrendsGlobal NK1/NK3 Receptor Antagonists Industry Growth and Trends Forecast to 2032112 pages · $3,450 USDMarket StructureGlobal NK1/NK3 Receptor Antagonists Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal NK1/NK3 Receptor Antagonists Market Outlook and Growth Opportunities 2026208 pages · $4,250 USDMarket Analysis & ForecastGlobal NK1/NK3 Receptor Antagonists Market Analysis and Forecast 2026-2032200 pages · $4,950 USD

Market perspective

The global NK1/NK3 Receptor Antagonists market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a CAGR of xx% over 2026-2032.

The North America market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026-2032.

The Europe market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for NK1/NK3 Receptor Antagonists is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of NK1/NK3 Receptor Antagonists include Chia Tai Tianqing Pharmaceutical, Yichang Humanwell Pharmaceutical, Qilu Pharmaceutical, Merck, Luoxin Pharmaceutical, Jiangsu Hengrui Pharmaceuticals, Helsinn Healthcare, Hansoh Pharma and Fresenius Kabi, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report provides a structured, data-driven view of the global NK1/NK3 Receptor Antagonists market, combining harmonized quantitative metrics with targeted qualitative insight to support business and growth strategy, market positioning, and capital allocation.

The NK1/NK3 Receptor Antagonists market size, estimates, and forecasts are presented in terms of sales volume (k units) and revenue (US$ million), with 2025 as the base year and historical and forecast data for 2021-2032. The report segments the global NK1/NK3 Receptor Antagonists market by Type, Application, region/country, and company, provides regional market sizes at the segment level, profiles the competitive landscape and key players and their market ranks, and reviews technology trends and new product developments relevant to NK1/NK3 Receptor Antagonists.

Key Companies & Market Share Insights

This section analyzes the strategies and performance of leading manufacturers in the global NK1/NK3 Receptor Antagonists market, including portfolio focus, innovation and product development, mergers and acquisitions, collaborations, and geographic expansion used to sustain or enhance competitive positions. It also summarizes recent corporate developments and key financial indicators and provides global revenue, price, and sales volume data by manufacturer for 2020-2025, enabling benchmarking of scale, pricing, and market share and supporting assessment of market concentration through indicators such as CR5 and CR10.

NK1/NK3 Receptor Antagonists Market by Company

Chia Tai Tianqing Pharmaceutical

Yichang Humanwell Pharmaceutical

Qilu Pharmaceutical

Merck

Luoxin Pharmaceutical

Jiangsu Hengrui Pharmaceuticals

Helsinn Healthcare

Hansoh Pharma

Fresenius Kabi

Beijing Sihuan Pharmaceutical

Bayer

Astellas

Torrent Pharmaceuticals

TerSera Therapeutics

Heron Therapeutics

Glenmark

NK1/NK3 Receptor Antagonists Segment by Type

NK1 Receptor Antagonist

NK3 Receptor Antagonist

Dual Antagonist

NK1/NK3 Receptor Antagonists Segment by Application

Hospital

Specialty Clinic

NK1/NK3 Receptor Antagonists Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global NK1/NK3 Receptor Antagonists market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of NK1/NK3 Receptor Antagonists and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of NK1/NK3 Receptor Antagonists.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the study scope of this report, executive summary of market segments by type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of NK1/NK3 Receptor Antagonists manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.

Chapter 4: Sales, revenue of NK1/NK3 Receptor Antagonists in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.

Chapter 5: Introduces market segments by application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.

Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 7, 8, 9, 10 and 11: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.

Chapter 12: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics.

Chapter 13: Concluding Insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Major Company of NK1 Receptor Antagonist Table 2. Major Company of NK3 Receptor Antagonist Table 3. Major Company of Dual Antagonist Table 4. Global NK1/NK3 Receptor Antagonists Sales by Type (2021 VS 2025 VS 2032) & (US$ Million) Table 5. Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 6. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type (2021-2026) Table 7. Global NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 8. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type (2021-2026) Table 9. Global NK1/NK3 Receptor Antagonists Price by Type (2021-2026) & (USD/unit) Table 10. Global NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (k units) Table 11. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type (2027-2032) Table 12. Global NK1/NK3 Receptor Antagonists Sales by Type (2027-2032) & (US$ Million) Table 13. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type (2027-2032) Table 14. Global NK1/NK3 Receptor Antagonists Price by Type (2027-2032) & (USD/unit) Table 15. North America NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 16. North America NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 17. Europe NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 18. Europe NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 19. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 20. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 21. Latin America NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 22. Latin America NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 23. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (k units) Table 24. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Type (2021-2026) & (US$ Million) Table 25. NK1/NK3 Receptor Antagonists Industry Trends Table 26. NK1/NK3 Receptor Antagonists Industry Drivers Table 27. NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges Table 28. NK1/NK3 Receptor Antagonists Industry Restraints Table 29. Global NK1/NK3 Receptor Antagonists Sales Revenue by Company (US$ Million) & (2021-2026) Table 30. Global NK1/NK3 Receptor Antagonists Revenue Market Share by Company (2021-2026) Table 31. Global NK1/NK3 Receptor Antagonists Sales by Company (2021-2026) & (k units) Table 32. Global NK1/NK3 Receptor Antagonists Sales Share by Company (2021-2026) Table 33. Global NK1/NK3 Receptor Antagonists Market Price by Company (2021-2026) & (USD/unit) Table 34. Global NK1/NK3 Receptor Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026 Table 35. Global NK1/NK3 Receptor Antagonists Major Company Production Sites and Headquarters Table 36. Global NK1/NK3 Receptor Antagonists Company, Product Type & Application Table 37. Global NK1/NK3 Receptor Antagonists Company Establishment Date Table 38. Global Company Market Concentration Ratio (CR5 and HHI) Table 39. Global NK1/NK3 Receptor Antagonists by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 40. Global NK1/NK3 Receptor Antagonists Market Size Comparison by Region (US$ Million): 2021 VS 2025 VS 2032 Table 41. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (k units) Table 42. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Region (2021-2026) Table 43. Global NK1/NK3 Receptor Antagonists Sales by Region (2021-2026) & (US$ Million) Table 44. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Region (2021-2026) Table 45. Global NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 46. Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032) & (k units) Table 47. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Region (2027-2032) Table 48. Global NK1/NK3 Receptor Antagonists Sales by Region (2027-2032) & (US$ Million) Table 49. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Region (2027-2032) Table 50. Global NK1/NK3 Receptor Antagonists Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2027-2032) Table 51. Global NK1/NK3 Receptor Antagonists Sales by Application (2021 VS 2025 VS 2032) & (US$ Million) Table 52. Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 53. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application (2021-2026) Table 54. Global NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 55. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application (2021-2026) Table 56. Global NK1/NK3 Receptor Antagonists Price by Application (2021-2026) & (USD/unit) Table 57. Global NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (k units) Table 58. Global NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application (2027-2032) Table 59. Global NK1/NK3 Receptor Antagonists Sales by Application (2027-2032) & (US$ Million) Table 60. Global NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application (2027-2032) Table 61. Global NK1/NK3 Receptor Antagonists Price by Application (2027-2032) & (USD/unit) Table 62. North America NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 63. North America NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 64. Europe NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 65. Europe NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 66. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 67. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 68. Latin America NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 69. Latin America NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 70. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (k units) Table 71. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Application (2021-2026) & (US$ Million) Table 72. Chia Tai Tianqing Pharmaceutical Company Information Table 73. Chia Tai Tianqing Pharmaceutical Business Overview Table 74. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 75. Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 76. Chia Tai Tianqing Pharmaceutical Recent Development Table 77. Yichang Humanwell Pharmaceutical Company Information Table 78. Yichang Humanwell Pharmaceutical Business Overview Table 79. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 80. Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 81. Yichang Humanwell Pharmaceutical Recent Development Table 82. Qilu Pharmaceutical Company Information Table 83. Qilu Pharmaceutical Business Overview Table 84. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 85. Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 86. Qilu Pharmaceutical Recent Development Table 87. Merck Company Information Table 88. Merck Business Overview Table 89. Merck NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 90. Merck NK1/NK3 Receptor Antagonists Product Portfolio Table 91. Merck Recent Development Table 92. Luoxin Pharmaceutical Company Information Table 93. Luoxin Pharmaceutical Business Overview Table 94. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 95. Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 96. Luoxin Pharmaceutical Recent Development Table 97. Jiangsu Hengrui Pharmaceuticals Company Information Table 98. Jiangsu Hengrui Pharmaceuticals Business Overview Table 99. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 100. Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 101. Jiangsu Hengrui Pharmaceuticals Recent Development Table 102. Helsinn Healthcare Company Information Table 103. Helsinn Healthcare Business Overview Table 104. Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 105. Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio Table 106. Helsinn Healthcare Recent Development Table 107. Hansoh Pharma Company Information Table 108. Hansoh Pharma Business Overview Table 109. Hansoh Pharma NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 110. Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio Table 111. Hansoh Pharma Recent Development Table 112. Fresenius Kabi Company Information Table 113. Fresenius Kabi Business Overview Table 114. Fresenius Kabi NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 115. Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio Table 116. Fresenius Kabi Recent Development Table 117. Beijing Sihuan Pharmaceutical Company Information Table 118. Beijing Sihuan Pharmaceutical Business Overview Table 119. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 120. Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio Table 121. Beijing Sihuan Pharmaceutical Recent Development Table 122. Bayer Company Information Table 123. Bayer Business Overview Table 124. Bayer NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 125. Bayer NK1/NK3 Receptor Antagonists Product Portfolio Table 126. Bayer Recent Development Table 127. Astellas Company Information Table 128. Astellas Business Overview Table 129. Astellas NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 130. Astellas NK1/NK3 Receptor Antagonists Product Portfolio Table 131. Astellas Recent Development Table 132. Torrent Pharmaceuticals Company Information Table 133. Torrent Pharmaceuticals Business Overview Table 134. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 135. Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio Table 136. Torrent Pharmaceuticals Recent Development Table 137. TerSera Therapeutics Company Information Table 138. TerSera Therapeutics Business Overview Table 139. TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 140. TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 141. TerSera Therapeutics Recent Development Table 142. Heron Therapeutics Company Information Table 143. Heron Therapeutics Business Overview Table 144. Heron Therapeutics NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 145. Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio Table 146. Heron Therapeutics Recent Development Table 147. Glenmark Company Information Table 148. Glenmark Business Overview Table 149. Glenmark NK1/NK3 Receptor Antagonists Sales (k units), Revenue (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 150. Glenmark NK1/NK3 Receptor Antagonists Product Portfolio Table 151. Glenmark Recent Development Table 152. North America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 153. North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 154. North America NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 155. North America NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032) & (k units) Table 156. North America NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Country (2027-2032) Table 157. North America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 158. North America NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 159. North America NK1/NK3 Receptor Antagonists Market Share by Country (2021-2026) Table 160. North America NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 161. North America NK1/NK3 Receptor Antagonists Market Share Forecast by Country (2027-2032) Table 162. Europe NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 163. Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 164. Europe NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 165. Europe NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032) & (k units) Table 166. Europe NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Country (2027-2032) Table 167. Europe NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 168. Europe NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 169. Europe NK1/NK3 Receptor Antagonists Market Share by Country (2021-2026) Table 170. Europe NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 171. Europe NK1/NK3 Receptor Antagonists Market Share Forecast by Country (2027-2032) Table 172. Asia-Pacific NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 173. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 174. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 175. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032) & (k units) Table 176. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Country (2027-2032) Table 177. Asia-Pacific NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 178. Asia-Pacific NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 179. Asia-Pacific NK1/NK3 Receptor Antagonists Market Share by Country (2021-2026) Table 180. Asia-Pacific NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 181. Asia-Pacific NK1/NK3 Receptor Antagonists Market Share Forecast by Country (2027-2032) Table 182. Latin America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 183. Latin America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 184. Latin America NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 185. Latin America NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032) & (k units) Table 186. Latin America NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Country (2027-2032) Table 187. Latin America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 188. Latin America NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 189. Latin America NK1/NK3 Receptor Antagonists Market Share by Country (2021-2026) Table 190. Latin America NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 191. Latin America NK1/NK3 Receptor Antagonists Market Share Forecast by Country (2027-2032) Table 192. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (k units): 2021 VS 2025 VS 2032 Table 193. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2026) & (k units) Table 194. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share by Country (2021-2026) Table 195. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032) & (k units) Table 196. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share Forecast by Country (2027-2032) Table 197. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country (US$ Million): 2021 VS 2025 VS 2032 Table 198. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026) & (US$ Million) Table 199. Middle East and Africa NK1/NK3 Receptor Antagonists Market Share by Country (2021-2026) Table 200. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032) & (US$ Million) Table 201. Middle East and Africa NK1/NK3 Receptor Antagonists Market Share Forecast by Country (2027-2032) Table 202. Key Raw Materials Table 203. Raw Materials Key Suppliers Table 204. NK1/NK3 Receptor Antagonists Distributors List Table 205. NK1/NK3 Receptor Antagonists Customers List Table 206. Research Programs/Design for This Report Table 207. Authors List of This Report Table 208. Secondary Sources Table 209. Primary Sources List of Figures Figure 1. NK1/NK3 Receptor Antagonists Image Figure 2. Global NK1/NK3 Receptor Antagonists Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global NK1/NK3 Receptor Antagonists Market Size (2021-2032) & (US$ Million) Figure 4. Global NK1/NK3 Receptor Antagonists Sales (2021-2032) & (k units) Figure 5. NK1 Receptor Antagonist Image Figure 6. Global NK1 Receptor Antagonist Sales YoY Growth (2021-2032) & (k units) Figure 7. NK3 Receptor Antagonist Image Figure 8. Global NK3 Receptor Antagonist Sales YoY Growth (2021-2032) & (k units) Figure 9. Dual Antagonist Image Figure 10. Global Dual Antagonist Sales YoY Growth (2021-2032) & (k units) Figure 11. Global NK1/NK3 Receptor Antagonists Market Size Overview by Type (2021-2032) & (US$ Million) Figure 12. Global NK1/NK3 Receptor Antagonists Market Share by Type 2025 VS 2032 Figure 13. North America NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type in 2025 Figure 14. North America NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type in 2025 Figure 15. Europe NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type in 2025 Figure 16. Europe NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type in 2025 Figure 17. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type in 2025 Figure 18. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type in 2025 Figure 19. Latin America NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type in 2025 Figure 20. Latin America NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type in 2025 Figure 21. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Type in 2025 Figure 22. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share in Value by Type in 2025 Figure 23. Global Top 5 and 10 NK1/NK3 Receptor Antagonists Players Market Share by Revenue in 2025 Figure 24. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 25. Hospital Image Figure 26. Global Hospital Sales YoY Growth (2021-2032) & (k units) Figure 27. Specialty Clinic Image Figure 28. Global Specialty Clinic Sales YoY Growth (2021-2032) & (k units) Figure 29. Global NK1/NK3 Receptor Antagonists Market Size Overview by Application (2021-2032) & (US$ Million) Figure 30. Global NK1/NK3 Receptor Antagonists Market Share by Application 2025 VS 2032 Figure 31. North America NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application in 2025 Figure 32. North America NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application in 2025 Figure 33. Europe NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application in 2025 Figure 34. Europe NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application in 2025 Figure 35. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application in 2025 Figure 36. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application in 2025 Figure 37. Latin America NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application in 2025 Figure 38. Latin America NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application in 2025 Figure 39. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share in Volume by Application in 2025 Figure 40. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Market Share in Value by Application in 2025 Figure 41. North America NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 42. North America NK1/NK3 Receptor Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 43. North America NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 44. North America NK1/NK3 Receptor Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 45. Europe NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 46. Europe NK1/NK3 Receptor Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 47. Europe NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 48. Europe NK1/NK3 Receptor Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 49. Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 50. Asia-Pacific NK1/NK3 Receptor Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 51. Asia-Pacific NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 52. Asia-Pacific NK1/NK3 Receptor Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 53. Latin America NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 54. Latin America NK1/NK3 Receptor Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 55. Latin America NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 56. Latin America NK1/NK3 Receptor Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 57. Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country: 2021 VS 2025 VS 2032 (k units) Figure 58. Middle East and Africa NK1/NK3 Receptor Antagonists Sales Share by Country: 2021 VS 2025 VS 2032 Figure 59. Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country: 2021 VS 2025 VS 2032 (US$ Million) Figure 60. Middle East and Africa NK1/NK3 Receptor Antagonists Market Share by Country: 2021 VS 2025 VS 2032 Figure 61. NK1/NK3 Receptor Antagonists Value Chain Figure 62. Key Raw Materials Price Figure 63. Manufacturing Cost Structure Figure 64. NK1/NK3 Receptor Antagonists Production Mode & Process Figure 65. Direct Comparison with Distribution Share Figure 66. Distributors Profiles Figure 67. Years Considered Figure 68. Research Process Figure 69. Key Executives Interviewed

Scope & coverage.

Types
  • NK1 Receptor Antagonist
  • NK3 Receptor Antagonist
  • Dual Antagonist
Applications
  • Hospital
  • Specialty Clinic
Companies covered
  • Chia Tai Tianqing Pharmaceutical
  • Yichang Humanwell Pharmaceutical
  • Qilu Pharmaceutical
  • Merck
  • Luoxin Pharmaceutical
  • Jiangsu Hengrui Pharmaceuticals
  • Helsinn Healthcare
  • Hansoh Pharma
  • Fresenius Kabi
  • Beijing Sihuan Pharmaceutical
  • Bayer
  • Astellas
  • Torrent Pharmaceuticals
  • TerSera Therapeutics
  • Heron Therapeutics
  • Glenmark

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global NK1/NK3 Receptor Antagonists Market Size Estimates and Forecasts (2021-2032)
  4. 1.2.2 Global NK1/NK3 Receptor Antagonists Sales Estimates and Forecasts (2021-2032)
  5. 1.3 NK1/NK3 Receptor Antagonists Market by Type
  6. 1.3.1 NK1 Receptor Antagonist
  7. 1.3.2 NK3 Receptor Antagonist
  8. 1.3.3 Dual Antagonist
  9. 1.4 Global NK1/NK3 Receptor Antagonists Market Size by Type
  10. 1.4.1 Global NK1/NK3 Receptor Antagonists Market Size Overview by Type (2021-2032)
  11. 1.4.2 Global NK1/NK3 Receptor Antagonists Historic Market Size Review by Type (2021-2026)
  12. 1.4.3 Global NK1/NK3 Receptor Antagonists Forecasted Market Size by Type (2027-2032)
  13. 1.5 Key Regions Market Size by Type
  14. 1.5.1 North America NK1/NK3 Receptor Antagonists Sales Breakdown by Type (2021-2026)
  15. 1.5.2 Europe NK1/NK3 Receptor Antagonists Sales Breakdown by Type (2021-2026)
  16. 1.5.3 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Breakdown by Type (2021-2026)
  17. 1.5.4 South America NK1/NK3 Receptor Antagonists Sales Breakdown by Type (2021-2026)
  18. 1.5.5 Middle East and Africa NK1/NK3 Receptor Antagonists Sales Breakdown by Type (2021-2026)
2 Global Market Dynamics
  1. 2.1 NK1/NK3 Receptor Antagonists Industry Trends
  2. 2.2 NK1/NK3 Receptor Antagonists Industry Drivers
  3. 2.3 NK1/NK3 Receptor Antagonists Industry Opportunities and Challenges
  4. 2.4 NK1/NK3 Receptor Antagonists Industry Restraints
3 Market Competitive Landscape by Company
  1. 3.1 Global Top Players by NK1/NK3 Receptor Antagonists Revenue (2021-2026)
  2. 3.2 Global Top Players by NK1/NK3 Receptor Antagonists Sales (2021-2026)
  3. 3.3 Global Top Players by NK1/NK3 Receptor Antagonists Price (2021-2026)
  4. 3.4 Global NK1/NK3 Receptor Antagonists Industry Company Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global NK1/NK3 Receptor Antagonists Major Company Production Sites & Headquarters
  6. 3.6 Global NK1/NK3 Receptor Antagonists Company, Product Type & Application
  7. 3.7 Global NK1/NK3 Receptor Antagonists Company Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global NK1/NK3 Receptor Antagonists Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 NK1/NK3 Receptor Antagonists Players Market Share by Revenue in 2025
  11. 3.8.3 2025 NK1/NK3 Receptor Antagonists Tier 1, Tier 2, and Tier 3
4 NK1/NK3 Receptor Antagonists Regional Status and Outlook
  1. 4.1 Global NK1/NK3 Receptor Antagonists Market Size and CAGR by Region: 2021 VS 2025 VS 2032
  2. 4.2 Global NK1/NK3 Receptor Antagonists Historic Market Size by Region
  3. 4.2.1 Global NK1/NK3 Receptor Antagonists Sales in Volume by Region (2021-2026)
  4. 4.2.2 Global NK1/NK3 Receptor Antagonists Sales in Value by Region (2021-2026)
  5. 4.2.3 Global NK1/NK3 Receptor Antagonists Sales (Volume & Value), Price and Gross Margin (2021-2026)
  6. 4.3 Global NK1/NK3 Receptor Antagonists Forecasted Market Size by Region
  7. 4.3.1 Global NK1/NK3 Receptor Antagonists Sales in Volume by Region (2027-2032)
  8. 4.3.2 Global NK1/NK3 Receptor Antagonists Sales in Value by Region (2027-2032)
  9. 4.3.3 Global NK1/NK3 Receptor Antagonists Sales (Volume & Value), Price and Gross Margin (2027-2032)
5 NK1/NK3 Receptor Antagonists by Application
  1. 5.1 NK1/NK3 Receptor Antagonists Market by Application
  2. 5.1.1 Hospital
  3. 5.1.2 Specialty Clinic
  4. 5.2 Global NK1/NK3 Receptor Antagonists Market Size by Application
  5. 5.2.1 Global NK1/NK3 Receptor Antagonists Market Size Overview by Application (2021-2032)
  6. 5.2.2 Global NK1/NK3 Receptor Antagonists Historic Market Size Review by Application (2021-2026)
  7. 5.2.3 Global NK1/NK3 Receptor Antagonists Forecasted Market Size by Application (2027-2032)
  8. 5.3 Key Regions Market Size by Application
  9. 5.3.1 North America NK1/NK3 Receptor Antagonists Sales Breakdown by Application (2021-2026)
  10. 5.3.2 Europe NK1/NK3 Receptor Antagonists Sales Breakdown by Application (2021-2026)
  11. 5.3.3 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Breakdown by Application (2021-2026)
  12. 5.3.4 South America NK1/NK3 Receptor Antagonists Sales Breakdown by Application (2021-2026)
  13. 5.3.5 Middle East and Africa NK1/NK3 Receptor Antagonists Sales Breakdown by Application (2021-2026)
6 Company Profiles
  1. 6.1 Chia Tai Tianqing Pharmaceutical
  2. 6.1.1 Chia Tai Tianqing Pharmaceutical Company Information
  3. 6.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
  4. 6.1.3 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  5. 6.1.4 Chia Tai Tianqing Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  6. 6.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
  7. 6.2 Yichang Humanwell Pharmaceutical
  8. 6.2.1 Yichang Humanwell Pharmaceutical Company Information
  9. 6.2.2 Yichang Humanwell Pharmaceutical Business Overview
  10. 6.2.3 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  11. 6.2.4 Yichang Humanwell Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  12. 6.2.5 Yichang Humanwell Pharmaceutical Recent Developments
  13. 6.3 Qilu Pharmaceutical
  14. 6.3.1 Qilu Pharmaceutical Company Information
  15. 6.3.2 Qilu Pharmaceutical Business Overview
  16. 6.3.3 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  17. 6.3.4 Qilu Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  18. 6.3.5 Qilu Pharmaceutical Recent Developments
  19. 6.4 Merck
  20. 6.4.1 Merck Company Information
  21. 6.4.2 Merck Business Overview
  22. 6.4.3 Merck NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  23. 6.4.4 Merck NK1/NK3 Receptor Antagonists Product Portfolio
  24. 6.4.5 Merck Recent Developments
  25. 6.5 Luoxin Pharmaceutical
  26. 6.5.1 Luoxin Pharmaceutical Company Information
  27. 6.5.2 Luoxin Pharmaceutical Business Overview
  28. 6.5.3 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  29. 6.5.4 Luoxin Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  30. 6.5.5 Luoxin Pharmaceutical Recent Developments
  31. 6.6 Jiangsu Hengrui Pharmaceuticals
  32. 6.6.1 Jiangsu Hengrui Pharmaceuticals Company Information
  33. 6.6.2 Jiangsu Hengrui Pharmaceuticals Business Overview
  34. 6.6.3 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  35. 6.6.4 Jiangsu Hengrui Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  36. 6.6.5 Jiangsu Hengrui Pharmaceuticals Recent Developments
  37. 6.7 Helsinn Healthcare
  38. 6.7.1 Helsinn Healthcare Company Information
  39. 6.7.2 Helsinn Healthcare Business Overview
  40. 6.7.3 Helsinn Healthcare NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  41. 6.7.4 Helsinn Healthcare NK1/NK3 Receptor Antagonists Product Portfolio
  42. 6.7.5 Helsinn Healthcare Recent Developments
  43. 6.8 Hansoh Pharma
  44. 6.8.1 Hansoh Pharma Company Information
  45. 6.8.2 Hansoh Pharma Business Overview
  46. 6.8.3 Hansoh Pharma NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  47. 6.8.4 Hansoh Pharma NK1/NK3 Receptor Antagonists Product Portfolio
  48. 6.8.5 Hansoh Pharma Recent Developments
  49. 6.9 Fresenius Kabi
  50. 6.9.1 Fresenius Kabi Company Information
  51. 6.9.2 Fresenius Kabi Business Overview
  52. 6.9.3 Fresenius Kabi NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  53. 6.9.4 Fresenius Kabi NK1/NK3 Receptor Antagonists Product Portfolio
  54. 6.9.5 Fresenius Kabi Recent Developments
  55. 6.10 Beijing Sihuan Pharmaceutical
  56. 6.10.1 Beijing Sihuan Pharmaceutical Company Information
  57. 6.10.2 Beijing Sihuan Pharmaceutical Business Overview
  58. 6.10.3 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  59. 6.10.4 Beijing Sihuan Pharmaceutical NK1/NK3 Receptor Antagonists Product Portfolio
  60. 6.10.5 Beijing Sihuan Pharmaceutical Recent Developments
  61. 6.11 Bayer
  62. 6.11.1 Bayer Company Information
  63. 6.11.2 Bayer Business Overview
  64. 6.11.3 Bayer NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  65. 6.11.4 Bayer NK1/NK3 Receptor Antagonists Product Portfolio
  66. 6.11.5 Bayer Recent Developments
  67. 6.12 Astellas
  68. 6.12.1 Astellas Company Information
  69. 6.12.2 Astellas Business Overview
  70. 6.12.3 Astellas NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  71. 6.12.4 Astellas NK1/NK3 Receptor Antagonists Product Portfolio
  72. 6.12.5 Astellas Recent Developments
  73. 6.13 Torrent Pharmaceuticals
  74. 6.13.1 Torrent Pharmaceuticals Company Information
  75. 6.13.2 Torrent Pharmaceuticals Business Overview
  76. 6.13.3 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  77. 6.13.4 Torrent Pharmaceuticals NK1/NK3 Receptor Antagonists Product Portfolio
  78. 6.13.5 Torrent Pharmaceuticals Recent Developments
  79. 6.14 TerSera Therapeutics
  80. 6.14.1 TerSera Therapeutics Company Information
  81. 6.14.2 TerSera Therapeutics Business Overview
  82. 6.14.3 TerSera Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  83. 6.14.4 TerSera Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  84. 6.14.5 TerSera Therapeutics Recent Developments
  85. 6.15 Heron Therapeutics
  86. 6.15.1 Heron Therapeutics Company Information
  87. 6.15.2 Heron Therapeutics Business Overview
  88. 6.15.3 Heron Therapeutics NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  89. 6.15.4 Heron Therapeutics NK1/NK3 Receptor Antagonists Product Portfolio
  90. 6.15.5 Heron Therapeutics Recent Developments
  91. 6.16 Glenmark
  92. 6.16.1 Glenmark Company Information
  93. 6.16.2 Glenmark Business Overview
  94. 6.16.3 Glenmark NK1/NK3 Receptor Antagonists Sales, Revenue and Gross Margin (2021-2026)
  95. 6.16.4 Glenmark NK1/NK3 Receptor Antagonists Product Portfolio
  96. 6.16.5 Glenmark Recent Developments
7 North America by Country
  1. 7.1 North America NK1/NK3 Receptor Antagonists Sales by Country
  2. 7.1.1 North America NK1/NK3 Receptor Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 7.1.2 North America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  4. 7.1.3 North America NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032)
  5. 7.2 North America NK1/NK3 Receptor Antagonists Market Size by Country
  6. 7.2.1 North America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 7.2.2 North America NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026)
  8. 7.2.3 North America NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032)
8 Europe by Country
  1. 8.1 Europe NK1/NK3 Receptor Antagonists Sales by Country
  2. 8.1.1 Europe NK1/NK3 Receptor Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 8.1.2 Europe NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  4. 8.1.3 Europe NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032)
  5. 8.2 Europe NK1/NK3 Receptor Antagonists Market Size by Country
  6. 8.2.1 Europe NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 8.2.2 Europe NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026)
  8. 8.2.3 Europe NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032)
9 Asia-Pacific by Country
  1. 9.1 Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Country
  2. 9.1.1 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 9.1.2 Asia-Pacific NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  4. 9.1.3 Asia-Pacific NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032)
  5. 9.2 Asia-Pacific NK1/NK3 Receptor Antagonists Market Size by Country
  6. 9.2.1 Asia-Pacific NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 9.2.2 Asia-Pacific NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026)
  8. 9.2.3 Asia-Pacific NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032)
10 South America by Country
  1. 10.1 South America NK1/NK3 Receptor Antagonists Sales by Country
  2. 10.1.1 South America NK1/NK3 Receptor Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 10.1.2 South America NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  4. 10.1.3 South America NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032)
  5. 10.2 South America NK1/NK3 Receptor Antagonists Market Size by Country
  6. 10.2.1 South America NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 10.2.2 South America NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026)
  8. 10.2.3 South America NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032)
11 Middle East and Africa by Country
  1. 11.1 Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country
  2. 11.1.1 Middle East and Africa NK1/NK3 Receptor Antagonists Sales Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  3. 11.1.2 Middle East and Africa NK1/NK3 Receptor Antagonists Sales by Country (2021-2026)
  4. 11.1.3 Middle East and Africa NK1/NK3 Receptor Antagonists Sales Forecast by Country (2027-2032)
  5. 11.2 Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country
  6. 11.2.1 Middle East and Africa NK1/NK3 Receptor Antagonists Market Size Growth Rate (CAGR) by Country: 2021 VS 2025 VS 2032
  7. 11.2.2 Middle East and Africa NK1/NK3 Receptor Antagonists Market Size by Country (2021-2026)
  8. 11.2.3 Middle East and Africa NK1/NK3 Receptor Antagonists Market Size Forecast by Country (2027-2032)
12 Value Chain and Sales Channels Analysis
  1. 12.1 NK1/NK3 Receptor Antagonists Value Chain Analysis
  2. 12.1.1 NK1/NK3 Receptor Antagonists Key Raw Materials
  3. 12.1.2 Key Raw Materials Price
  4. 12.1.3 Raw Materials Key Suppliers
  5. 12.1.4 Manufacturing Cost Structure
  6. 12.1.5 NK1/NK3 Receptor Antagonists Production Mode & Process
  7. 12.2 NK1/NK3 Receptor Antagonists Sales Channels Analysis
  8. 12.2.1 Direct Comparison with Distribution Share
  9. 12.2.2 NK1/NK3 Receptor Antagonists Distributors
  10. 12.2.3 NK1/NK3 Receptor Antagonists Customers
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources
    8. 14.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,450USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research, Inc.
    Talk to an analyst